Targeting innate immune mediators in type 1 and type 2 diabetes

Research output: Contribution to journal › Review › Research › peer-review

Standard

Targeting innate immune mediators in type 1 and type 2 diabetes. / Donath, Marc Y.; Dinarello, Charles A.; Mandrup-Poulsen, Thomas.

In: Nature Reviews. Immunology, Vol. 19, No. 12, 2019, p. 734-746.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Donath, MY, Dinarello, CA & Mandrup-Poulsen, T 2019, 'Targeting innate immune mediators in type 1 and type 2 diabetes', Nature Reviews. Immunology, vol. 19, no. 12, pp. 734-746. https://doi.org/10.1038/s41577-019-0213-9

APA

Donath, M. Y., Dinarello, C. A., & Mandrup-Poulsen, T. (2019). Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews. Immunology, 19(12), 734-746. https://doi.org/10.1038/s41577-019-0213-9

Vancouver

Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews. Immunology. 2019;19(12):734-746. https://doi.org/10.1038/s41577-019-0213-9

Author

Donath, Marc Y. ; Dinarello, Charles A. ; Mandrup-Poulsen, Thomas. / Targeting innate immune mediators in type 1 and type 2 diabetes. In: Nature Reviews. Immunology. 2019 ; Vol. 19, No. 12. pp. 734-746.

Bibtex

@article{09260196ab184b55a7501e453b52eb13,
title = "Targeting innate immune mediators in type 1 and type 2 diabetes",
abstract = "Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.",
author = "Donath, {Marc Y.} and Dinarello, {Charles A.} and Thomas Mandrup-Poulsen",
year = "2019",
doi = "10.1038/s41577-019-0213-9",
language = "English",
volume = "19",
pages = "734--746",
journal = "Nature Reviews. Immunology",
issn = "1474-1733",
publisher = "nature publishing group",
number = "12",

}

RIS

TY - JOUR

T1 - Targeting innate immune mediators in type 1 and type 2 diabetes

AU - Donath, Marc Y.

AU - Dinarello, Charles A.

AU - Mandrup-Poulsen, Thomas

PY - 2019

Y1 - 2019

N2 - Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.

AB - Type 1 and type 2 diabetes are characterized by chronic inflammation; both diseases involve pancreatic islet inflammation, while systemic low-grade inflammation is a feature of obesity and type 2 diabetes. Long-term activation of the innate immune system impairs insulin secretion and action, and inflammation also contributes to macrovascular and microvascular complications of diabetes. However, despite strong preclinical evidence and proof-of-principle clinical trials demonstrating that targeting inflammatory pathways can prevent cardiovascular disease and other complications in patients with diabetes, there are still no approved treatments for diabetes that target innate immune mediators. Here, we review recent advances in our understanding of the inflammatory pathogenesis of type 1 and type 2 diabetes from a translational angle and point out the critical gaps in knowledge that need to be addressed to guide drug development.

U2 - 10.1038/s41577-019-0213-9

DO - 10.1038/s41577-019-0213-9

M3 - Review

C2 - 31501536

VL - 19

SP - 734

EP - 746

JO - Nature Reviews. Immunology

JF - Nature Reviews. Immunology

SN - 1474-1733

IS - 12

ER -

ID: 231901182